Literature DB >> 25066130

Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects.

Chelsia Qiuxia Wang1, Vaidehi Krishnan2, Lavina Sierra Tay2, Desmond Wai Loon Chin2, Cai Ping Koh2, Jing Yuan Chooi2, Giselle Sek Suan Nah1, Linsen Du2, Bindya Jacob2, Namiko Yamashita2, Soak Kuan Lai2, Tuan Zea Tan2, Seiichi Mori2, Ichiro Tanuichi3, Vinay Tergaonkar4, Yoshiaki Ito5, Motomi Osato6.   

Abstract

The RUNX genes encode transcription factors involved in development and human disease. RUNX1 and RUNX3 are frequently associated with leukemias, yet the basis for their involvement in leukemogenesis is not fully understood. Here, we show that Runx1;Runx3 double-knockout (DKO) mice exhibited lethal phenotypes due to bone marrow failure and myeloproliferative disorder. These contradictory clinical manifestations are reminiscent of human inherited bone marrow failure syndromes such as Fanconi anemia (FA), caused by defective DNA repair. Indeed, Runx1;Runx3 DKO cells showed mitomycin C hypersensitivity, due to impairment of monoubiquitinated-FANCD2 recruitment to DNA damage foci, although FANCD2 monoubiquitination in the FA pathway was unaffected. RUNX1 and RUNX3 interact with FANCD2 independently of CBFβ, suggesting a nontranscriptional role for RUNX in DNA repair. These findings suggest that RUNX dysfunction causes DNA repair defect, besides transcriptional misregulation, and promotes the development of leukemias and other cancers.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25066130     DOI: 10.1016/j.celrep.2014.06.046

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  41 in total

Review 1.  The RUNX complex: reaching beyond haematopoiesis into immunity.

Authors:  Dominic Chih-Cheng Voon; Yit Teng Hor; Yoshiaki Ito
Journal:  Immunology       Date:  2015-10-25       Impact factor: 7.397

Review 2.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

4.  Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines.

Authors:  Hiroki Hosoi; Akiko Niibori-Nambu; Giselle Sek Suan Nah; Avinash Govind Bahirvani; Michelle Meng Huang Mok; Takaomi Sanda; Alan Prem Kumar; Daniel G Tenen; Yoshiaki Ito; Takashi Sonoki; Motomi Osato
Journal:  Gene       Date:  2021-01-12       Impact factor: 3.688

5.  Aurora kinase and RUNX: Reaching beyond transcription.

Authors:  Linda Shyue Huey Chuang; Vaidehi Krishnan; Yoshiaki Ito
Journal:  Cell Cycle       Date:  2016-08-05       Impact factor: 4.534

6.  Aurora kinase-induced phosphorylation excludes transcription factor RUNX from the chromatin to facilitate proper mitotic progression.

Authors:  Linda Shyue Huey Chuang; Jian Ming Khor; Soak Kuan Lai; Shubham Garg; Vaidehi Krishnan; Cheng-Gee Koh; Sang Hyun Lee; Yoshiaki Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-23       Impact factor: 11.205

Review 7.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

Review 8.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

9.  Drugging DNA repair to target T-ALL cells.

Authors:  Yashodhara Dasgupta; Konstantin Golovine; Margaret Nieborowska-Skorska; Li Luo; Ksenia Matlawska-Wasowska; Charles G Mullighan; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2017-11-08

10.  Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.

Authors:  Kyoko Ito; Keisuke Ito
Journal:  Cell Stem Cell       Date:  2015-08-06       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.